Recruiting A Study of CDX-622 in Participants With Mild to Moderate Asthma NCT07330778 Conditions Asthma, Bronchial Diseases, Hypersensitivity, +7 more Locations University of California, San Francisco — San Francisco, California, United States The University of Kansas Medical Center — Kansas City, Kansas, United States Brigham and Women's Hospital — Boston, Massachusetts, United States University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC — Pittsburgh, Pennsylvania, United States View Trial Details
Recruiting Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma NCT07245368 Conditions Asthma, Bronchial Diseases, Hypersensitivity, +7 more Locations Emertitus Research Sydney — Botany, New South Wales, Australia Emeritus Research Camberwell — Camberwell, Victoria, Australia Linear — Joondalup, Western Australia, Australia Linear — Nedlands, Western Australia, Australia View more locations Show fewer locations Loading locations... View Trial Details
Completed A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2) NCT02266927 Conditions Mild to Moderate Asthma Locations Celerion — Belfast, Ireland View Trial Details
Completed Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma NCT00734292 Conditions Asthma, Bronchial Diseases, Hypersensitivity, +7 more Locations Investigational Site — Anaheim, California, United States Investigational Site — Mission Viejo, California, United States Investigational Site — Denver, Colorado, United States Investigational Site — Valrico, Florida, United States View more locations Show fewer locations Loading locations... View Trial Details
